New Horizons in Ovarian Cancer: Expert Insights into the Role of Genetic Biomarkers in Precision Therapy

October 10, 2021

Attendees of these regional meetings will gain an appreciation of the genes involved in the DNA damage response pathways and their role in tumorigenesis, the latest guidelines on genetic testing/counseling for mutations in this pathway, and the clinical implications of testing results (such as the use of PARP inhibitor for treatment). There will also be extensive discussion about the evolving role of the OB/GYN practitioner in genetic testing/counseling and management of ovarian cancer survivors on PARP inhibitor therapy.


Presented by Creative Educational Concepts, Inc.

Supported through independent educational grants from AstraZeneca and Merck.

This is an independent CME Satellite Event and is not part of the official ACOG District IV 2021 Annual District Meeting.

Target Audience

This activity is targeted to gynecologists, obstetricians, and other related healthcare professionals attending the 2021 American College of Obstetricians and Gynecologists (ACOG) Clinical District Meetings.

Learning Objectives

  • Review the DNA damage response (DDR) pathway and its role in tumorigenesis of ovarian cancers and outline the various mutations that cause defects in this pathway. 
  • Review the latest clinical recommendations on genetic testing and counseling in ovarian cancer and discuss the therapeutic implications of identifying mutations in the DDR, as well as other relevant markers of genomic instability (e.g., HRD). 
  • Discuss current and emerging clinical data regarding the safety and efficacy of PARP inhibitors in ovarian cancer patients.   
  • Assess the evolving role of OB/GYN practitioners for genetic testing/counseling in patients who are at risk for or have deficiencies in the HRR pathway and discuss multidisciplinary strategies to ensure the appropriate management of patients on PARP inhibitors.    

Additional Information

AttachmentSize
PDF icon Handout & References5.23 MB
PDF icon CEC Zoom Guide448.5 KB
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
10/10/2021
Course expires: 
11/10/2021
Event starts: 
10/10/2021 - 12:00pm
Event ends: 
10/10/2021 - 1:00pm
Rating: 
0

5 min Welcome and Introductions/Pre-test 

15 min The DNA Damage Response Pathway: BRCA and Beyond 

15 min PARP Inhibitors in Ovarian Cancer Treatment: A Possible Achilles Heel? 

20 min Improving Patient Outcomes in Ovarian Cancer: Practical Strategies for the OB/GYN Practice 

5 min Conversations with the Experts/Audience Q&A/Post-test 

On Demand
Armed Forces District
United States

Dr. Shannon N. Westin, MD, MPH
Associate Professor
Director, Early Drug Development and Phase I Trials
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas, MD Anderson Cancer Center

 

 

Dr. Westin received her doctorate of Medicine from the University of Florida College of Medicine.  She completed Obstetrics and Gynecology residency at the University of North Carolina – Chapel Hill and fellowship in Gynecologic Oncology at the University of Texas MD Anderson Cancer Center.  During fellowship, she received an MPH with a concentration in epidemiology from the University of Texas, School of Public Health. In addition to her training in Gynecologic Oncology, she also completed a short fellowship in Investigational Cancer Therapeutics.  She joined the faculty at The University of Texas MD Anderson Cancer Center in 2010. She has been honored as a K12 scholar, Andrew Sabin Family Fellow, and a Gynecologic Oncology Group (GOG) Foundation Scholar Investigator.

Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. Dr. Westin is a member of the NRG Oncology – GOG Developmental Therapeutics, Phase I, and Early Phase Protocol Oversight committees.  She is the co-PI for five major projects in her institution’s SPORE in Uterine Cancer and SPORE in Ovarian Cancer.  In addition, she is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies.

Dr. Westin has authored or co-authored greater than 150 scientific publications, book chapters and invited articles. She has been invited to lecture as an expert on clinical trials, genomic testing and targeted therapy in gynecologic malignancies in national and international venues. She was selected for the competitive American Society of Clinical Oncology (ASCO) Leadership Development program and serves on five ASCO committees including the Communications Committee and Gynecologic Cancer Guidelines Group. She currently serves on the Board of Directors for the Society of Gynecologic Oncology (SGO) and the GOG Foundation.  In addition to serving on the National Cancer Institute (NCI) Uterine Task Force and Gynecologic Cancer Steering Committee (GCSC), she serves as a co-chair of the GCSC Ovarian Cancer Task Force and the NCI Ovarian Cancer Clinical Trials Planning Meeting. As such, she is guiding development of future NCI trials designed to push the field forward and expand the role of precision medicine in ovarian cancer.


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Authors/Presenters:
Ursula Matulonis, MD–has disclosed that she is a consultant for AstraZeneca, Merck, NextCure, and Novartis. He receives financial or material support from DSMB and Symphogen. 

Angeles Alvarez Secord, MD– has disclosed that she receives grant/research supports from AbbVie, AstraZeneca, Clovis, Merck, and Oncoquest. 

Robert M. Wenham, MD, MS, FACOG, FACS–has disclosed that he is a consultant for GSK/Tesaro, Merck, Ovation Diagnostics, Regeneron, Seagen, Sonnet Biotherapeutics, and Shattuck Labs. He receives grant/research support from Merck. He is a major stock shareholder in Ovation Diagnostics and is on the speakers’ bureau for ONC Live and Curio Science.

Shannon N. Westin, MD, MPH–has disclosed that she is a consultant for AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis. She receives grant/research support from AstraZeneca, Clovis Oncology, GSK/Tesaro, and Novartis.

Content Reviewer: 
Justine Cooper Pickarski - has no relevant financial relationships to disclose in relation to the content of this activity.

 

 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Medicine (ACCME) 

CEC designates this live, virtual educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. Upon completion of a CE request form, statements of credit for physicians will be issued. 

 

   

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or register to take this course.